Risk factors for Pseudomonas aeruginosa acquisition in intensive care units: a prospective multicentre studyA.G. Venier, Rodolphe Thiébaut, Xavier Bertrand et al.|Journal of Hospital Infection|2014Cited by 128
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean‐Jacques Grob, Hubert Pehamberger, Thomas Jouary et al.|European Journal of Cancer|2012Cited by 43